Abstract: Surfaces and processes are provided for immobilization of multimer polypeptides that preserves the functionality and active conformation of the native multimeric polypeptides. The multimer polypeptide is a self-assembled multimer and comprises both a first and a second chimeric polypeptide.

Abstract: Methods are provided for determining the presence of antibodies in blood or a blood product, using immobilized self-assembled polypeptides comprising an ectodomain and being recognized by the antibodies. The self-assembled polypeptide comprises at least a first chimeric polypeptide. In the methods the functionality and active conformation of the immobilized and self-assembled polypeptides is preserved. Processes for making the immobilized self-assembled polypeptides are also provided.

Abstract: Multivalent anti-platelet glycoprotein I(b)alpha antibodies can cause severe side effects. The present disclosure provides humanized antibodies specifically recognizing glycoprotein I(b)alpha and lacking a Fc portion, therefore Bleeding Time do not interact with Fc receptor. The humanized antibodies are capable of preventing platelet activation and aggregation, and reducing thrombus size/growth and prevent vessel occlusion. They can be also very useful to decrease platelet-tumor cell interaction and decrease tumor metastasis. At therapeutic doses, the humanized antibodies lack the ability to induce platelet activation, induce thrombocytopenia; and/or prolong bleeding time.

Abstract: Methods for inhibiting platelet aggregation using glucagon-like peptide-1 receptor (GLP-1R) agonists are disclosed. GLP-1 receptors are demonstrated to be expressed in platelets and/or megakaryocytes. Activation of GLP-1 receptors by GLP-1 agonists, such as GLP-1 and exendin-4, inhibited thrombin-induced platelet aggregation.

Abstract: This application relates to agents capable of specifically recognizing GPIb?, a key receptor required for platelet adhesion and aggregation. More specifically, this application relates to monoclonal antibodies and derivatives thereof capable of specifically recognizing both the murine and the human GPIb?. These monoclonal antibodies and derivatives are particularly useful in the treatment or prevention of thrombosis as well as research tools.

Abstract: This application relates to agents capable of specifically recognizing GPIb?, a key receptor required for platelet adhesion and aggregation. More specifically, this application relates to monoclonal antibodies and derivatives thereof capable of specifically recognizing both the murine and the human GPIb?. These monoclonal antibodies and derivatives are particularly useful in the treatment or prevention of thrombosis as well as research tools.

Abstract: Monoclonal antibodies prepared against platelet ?3 integrin useful in antithrombotic therapy or in models of thrombosis, thrombocytopenia, and anti-angiogenesis. The antibodies are prepared using ?3 integrin deficient (?3?/?) mice immunized against platelets or ?3 integrin fragments.

Abstract: Monoclonal antibodies prepared against platelet ?3 integrin useful in antithrombotic therapy or in models of thrombosis, thrombocytopenia, and anti-angiogenesis. The antibodies are prepared using ?3 integrin deficient (?3?/?) mice immunized against platelets or ?3 integrin fragments.